Alexion Pharmaceuticals (ALXN) Stock Price, News & Analysis

Company Overview

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $182.50 to $182.50
• 50-Day Range: $179.45 to $186.61
• 52-Week Range: $99.91 to $187.45
• Volume: 10 shs
• Average Volume: 3.31 million shs
• Market Capitalization: $40.34 billion
• P/E Ratio: 59.64
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ALXN Stock Analysis - Frequently Asked Questions

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced its quarterly earnings data on Thursday, April, 29th. The biopharmaceutical company reported $3.52 earnings per share for the quarter, beating analysts' consensus estimates of $3.16 by $0.36. The business's quarterly revenue was up 13.3% compared to the same quarter last year.

Does Alexion Pharmaceuticals have any subsidiaries?

Alexion Pharmaceuticals subsidiaries include these companies: Portola Pharmaceuticals Inc., Achillion Pharmaceuticals, Syntimmune, Wilson Therapeutics, Synageva BioPharma Corp., Enobia Pharma Corp., Taligen Therapeutics Inc., and more.

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alexion Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Tesla (TSLA), Netflix (NFLX), Gilead Sciences (GILD) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 4/29/2021
• Today: 4/04/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALXN
• CIK: 899866
• Web: www.alexion.com
• Phone: 475-230-2596
• Fax: N/A
• Employees: 3,837
• Year Founded: 1992

Profitability

• EPS (Most Recent Fiscal Year): $11.60
• Trailing P/E Ratio: 59.64
• Forward P/E Ratio: 13.95
• P/E Growth: 0.93
• Net Income: $603.40 million
• Net Margins: 10.89%
• Pretax Margin: N/A
• Return on Equity: 23.43%
• Return on Assets: 15.06%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 4.52
• Quick Ratio: 3.96

Sales & Book Value

• Annual Sales: $6.07 billion
• Price / Sales: 6.65
• Cash Flow: $22.81 per share
• Price / Cash Flow: 8.00
• Book Value: $53.24 per share
• Price / Book: 3.43

Miscellaneous

• Outstanding Shares: 221,019,000
• Free Float: N/A
• Market Cap: $40.34 billion
• Optionable: Optionable
• Beta: 1.25